NASDAQ$SMTI
Sanara MedTech Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Sanara MedTech reported its Q4 2023 results, highlighting strategic and operational milestones including the acquisition of key assets and the launch of new products.
Sanara MedTech Inc. reported increased net revenues driven by sales growth across all major product lines. The company continues to hire experienced sales managers to drive growth in new territories and expand product sales in existing accounts.
- Achieved sales growth across all major product lines.
- Continued hiring experienced and talented sales managers.
- Focused on driving growth in new territories.
- Worked to increase product sales in existing accounts and expand usage in new specialty areas.
Headline financials
Revenue & EPS history
Sanara MedTech · Revenue · Quarterly
$17.7M
Revenue by segment
Sanara MedTech · $31.6M total across 2 segments · Q2 2023
- Soft tissue repair$15.8M—50.0%
- Bone fusion products$15.8M—50.0%
Forward guidance
Sanara MedTech Inc. is positioned for continued strong growth in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+0.1%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.6%
Avg return
30 days after
34%
22 / 65 earnings
Positive
+28.6%
Q4 2014
Best reaction
-25.0%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.3% | -12.1% | — | |
| Q1 2026 | +13.0% | +17.3% | +19.5% | |
| Q3 2025 | -23.4% | -24.9% | -7.6% | |
| Q2 2025 | -4.8% | -3.3% | +6.4% | |
| Q1 2025 | -9.0% | -11.2% | -17.9% | |
| Q4 2024 | -12.6% | -15.4% | -10.4% | |
| Q3 2024 | +6.3% | -1.0% | +2.5% | |
| Q2 2024 | +14.9% | +16.3% | +20.2% | |
| Q1 2024 | -5.0% | -2.9% | -0.5% | |
| Q4 2023 | -1.8% | -1.1% | -13.1% | |
| Q3 2023 | +18.8% | +15.3% | +37.5% | |
| Q2 2023 | -12.5% | -13.6% | -22.6% | |
| Q1 2023 | -5.0% | -9.2% | -5.9% | |
| Q4 2022 | -0.1% | -4.1% | +17.9% | |
| Q3 2022 | +4.1% | +7.2% | +3.2% | |
| Q2 2022 | +1.2% | -1.7% | +13.4% | |
| Q1 2022 | +5.0% | +2.3% | -12.2% | |
| Q4 2021 | +2.5% | +10.7% | -10.9% | |
| Q3 2021 | -1.6% | -2.2% | -15.8% | |
| Q2 2021 | -8.3% | -12.4% | -14.5% | |
| Q1 2021 | +5.2% | +14.9% | +28.7% | |
| Q4 2020 | +14.5% | +6.8% | -4.5% | |
| Q3 2020 | -4.5% | -4.3% | +15.7% | |
| Q2 2020 | +9.8% | +13.7% | +37.2% | |
| Q1 2020 | -20.7% | -18.2% | +28.8% | |
| Q4 2019 | -4.3% | +7.3% | +30.9% | |
| Q3 2019 | -3.9% | -5.7% | +5.1% | |
| Q2 2019 | -11.5% | -20.1% | -17.2% | |
| Q1 2019 | +0.0% | -16.7% | -16.7% | |
| Q4 2018 | +0.0% | -16.7% | -16.7% | |
| Q3 2018 | +0.0% | +0.0% | +0.0% | |
| Q2 2018 | -10.0% | -10.0% | -30.0% | |
| Q1 2018 | +20.0% | +0.0% | +20.0% | |
| Q4 2017 | +20.0% | +0.0% | +20.0% | |
| Q3 2017 | +0.0% | +0.0% | -14.3% | |
| Q2 2017 | +0.0% | +16.7% | +16.7% | |
| Q1 2017 | +0.0% | +0.0% | -22.2% | |
| Q4 2016 | +0.0% | +0.0% | -10.0% | |
| Q3 2016 | -20.0% | -20.0% | +0.0% | |
| Q2 2016 | +20.0% | +0.0% | +0.0% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +11.1% | — | — | |
| Q4 2014 | +28.6% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +14.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +16.7% | — | — | |
| Q4 2012 | -12.5% | — | — | |
| Q3 2012 | -16.7% | — | — | |
| Q2 2012 | +6.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -10.3% | — | — | |
| Q1 2011 | -11.1% | — | — | |
| Q4 2010 | +3.1% | — | — | |
| Q3 2010 | -25.0% | — | — | |
| Q2 2010 | +2.9% | — | — | |
| Q1 2010 | +5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro